| Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in … E Di Gennaro, M Barbarino, F Bruzzese, S De Lorenzo, M Caraglia, ... Journal of cellular physiology 195 (1), 139-150, 2003 | 183 | 2003 |
| New perspective for an old antidiabetic drug: metformin as anticancer agent A Leone, E Di Gennaro, F Bruzzese, A Avallone, A Budillon Advances in Nutrition and Cancer, 355-376, 2014 | 175 | 2014 |
| HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT F Bruzzese, A Leone, M Rocco, C Carbone, G Piro, M Caraglia, ... Journal of cellular physiology 226 (9), 2378-2390, 2011 | 156 | 2011 |
| Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients R Bei, A Budillon, L Masuelli, V Cereda, D Vitolo, E Di Gennaro, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2004 | 132 | 2004 |
| Acetylation of proteins as novel target for antitumor therapy E Di Gennaro, F Bruzzese, M Caraglia, A Abruzzese, A Budillon Amino acids 26, 435-441, 2004 | 120 | 2004 |
| Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis F Bruzzese, M Rocco, S Castelli, E Di Gennaro, A Desideri, A Budillon Molecular cancer therapeutics 8 (11), 3075-3087, 2009 | 110 | 2009 |
| Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation C Ciardiello, A Leone, P Lanuti, MS Roca, T Moccia, VR Minciacchi, ... Journal of Experimental & Clinical Cancer Research 38, 1-16, 2019 | 94 | 2019 |
| Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-α in head and neck cancer cells in vitro and in vivo F Bruzzese, E Di Gennaro, A Avallone, S Pepe, C Arra, M Caraglia, ... Clinical Cancer Research 12 (2), 617-625, 2006 | 93 | 2006 |
| Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed E Di Gennaro, F Bruzzese, S Pepe, A Leone, P Delrio, P Subbarayan, ... Cancer biology & therapy 8 (9), 782-791, 2009 | 86 | 2009 |
| EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-α-mediated apoptosis in epidermoid cancer cells M Caraglia, P Tagliaferri, M Marra, G Giuberti, A Budillon, E Di Gennaro, ... Cell Death & Differentiation 10 (2), 218-229, 2003 | 81 | 2003 |
| Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway A Leone, MS Roca, C Ciardiello, M Terranova-Barberio, C Vitagliano, ... Free Radical Biology and Medicine 89, 287-299, 2015 | 77 | 2015 |
| Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR 2 and CD 133, are not detectable in healthy peripheral and cord blood P Lanuti, G Rotta, C Almici, G Avvisati, A Budillon, P Doretto, N Malara, ... Cytometry Part A 89 (3), 259-270, 2016 | 71 | 2016 |
| Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression M Terranova-Barberio, MS Roca, AI Zotti, A Leone, F Bruzzese, ... Oncotarget 7 (7), 7715, 2016 | 70 | 2016 |
| Tissue transglutaminase: a new target to reverse cancer drug resistance A Budillon, C Carbone, E Di Gennaro Amino acids 44, 63-72, 2013 | 68 | 2013 |
| Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial F Caponigro, E Di Gennaro, F Ionna, F Longo, C Aversa, E Pavone, ... BMC cancer 16, 1-10, 2016 | 60 | 2016 |
| Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways F Bruzzese, B Pucci, MR Milone, C Ciardiello, R Franco, MI Chianese, ... Cell death & disease 4 (10), e878-e878, 2013 | 59 | 2013 |
| Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed A Avallone, ED Gennaro, L Silvestro, VR Iaffaioli, A Budillon Expert opinion on drug safety 13 (1), 113-129, 2014 | 58 | 2014 |
| Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells MR Milone, B Pucci, F Bruzzese, C Carbone, G Piro, S Costantini, ... Cell death & disease 4 (5), e641-e641, 2013 | 58 | 2013 |
| Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents A Budillon, E Di Gennaro, F Bruzzese, M Rocco, G Manzo, M Caraglia Recent patents on anti-cancer drug discovery 2 (2), 119-134, 2007 | 58 | 2007 |
| Caveolin‐1 overexpression is associated with simultaneous abnormal expression of the E‐cadherin/α–β catenins complex and multiple erbb receptors and with lymph nodes metastasis … L Masuelli, A Budillon, L Marzocchella, MA Mrozek, D Vitolo, ... Journal of cellular physiology 227 (9), 3344-3353, 2012 | 55 | 2012 |
Alfredo BudillonIstituto Tumori Napoli G. PascaleDirección de correo verificada de istitutotumori.na.it
